Table 1.

Dose levels and DLTs in the phase I study of temsirolimus and erlotinib in patients with advanced cancer

Dose Level	Erlotinib (oral, daily)	Temsirolimus (IV, weekly)	Number of patients treated	Number of patients eligible for DLT evaluation	Number of patients experiencing DLT
1A	100 mg	10 mg	1	1	0
1	100 mg	15 mg	15	9	2 (G3 dehydration, n=1; G3 acute renal failure, n=1)
2	100 mg	20 mg	5	3	0
3	100 mg	25 mg	4	3	0
Dose Expansion Phase	100 mg	25 mg	16	16	0

DLT, dose limiting toxicity; G, grade